Subscribe To Our Free Newsletter |
Aurobindo Pharma receives USFDA final approval for Deflazacort Tablets
The product will be launched in February 2024. The approved product has an estimated market size of US$ 67 million for the three months ending September2023, according to PTC Therapeutics Inc. Aurobindo now has a total of 502 ANDA approvals (482 Final approvals and 20 tentative approvals) from USFDA.